eligibility_summary
Include: ≥18, ECOG ≤2, FL grade 1–3a, relapsed/refractory after ≥2 lines incl anti‑CD20, active measurable disease, recovered from prior therapy, adequate marrow/organ function. WOCBP: negative test + contraception Exclude: recent therapy, prior PI3K/EZH2 inhibitor, allo SCT or auto <6 mo, major surgery <30 d, strong/mod CYP3A4 meds, CNS/CV disease, uncontrolled illness/infection, active HBV/HCV/CMV/HIV, GI malabsorption/can’t swallow, hypersensitivity, chronic ≥20 mg steroids, concurrent trials.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1/2 (withdrawn for feasibility) single-arm study in relapsed/refractory follicular lymphoma testing: 1) Tazemetostat—oral small-molecule EZH2 histone methyltransferase (PRC2) inhibitor that reduces H3K27me3 to re-express tumor suppressor genes (epigenetic therapy). 2) Umbralisib—oral small-molecule inhibitor of PI3K-delta (and CK1epsilon) that blocks B-cell PI3K/AKT survival/proliferation signaling (targeted therapy). 3) Ublituximab—glycoengineered anti-CD20 IgG1 monoclonal antibody that depletes malignant B cells via ADCC/complement (immunotherapy). Targets: CD20+ follicular lymphoma B cells, EZH2-driven epigenetic program, PI3K-delta/AKT pathway, potential immune modulation via CK1epsilon. Aims: safety and response, explore immune effects of dual EZH2+PI3K inhibition and tumor evolution by liquid biopsy.